Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree

Rhea-AI Summary

Lucid Diagnostics (Nasdaq: LUCD) was named the winner in its company size category in the GenomeWeb 2025 Best Places to Work program on November 20, 2025.

The award recognizes top workplaces across diagnostics and precision medicine for transparent communication, an inclusive environment, professional development, and collaborative culture. Lucid is described as a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed (Nasdaq: PAVM). Company leadership credited employees for the recognition and emphasized a focus on patients, culture, scientific rigor, and long-term commercial success.

Recognized as the leading company in its size category in program honoring the top workplaces across the diagnostics and precision-medicine sectors

NEW YORK, Nov. 20, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has been named the winner in its company size category of the GenomeWeb 2025 Best Places to Work program, one of five top-ranking honorees across the life sciences research, diagnostics and precision medicine sectors.

GenomeWeb  is the leading news organization serving the global community of professionals in molecular biology research and molecular diagnostics. Its annual Best Places to Work program honors companies that have built strong, positive workplaces characterized by "transparent communication, an inclusive work environment, a commitment to professional development, and a culture of collaboration."

"We couldn't be more proud to be recognized by GenomeWeb and by our employees as one of the best places to work in our industry," said Shaun O'Neil, President and Chief Operating Officer of Lucid Diagnostics. "At Lucid, people and patients come first. Our team is unwavering in its commitment to a positive culture of service to patients and to each other, grounded in a high standards of excellence, scientific rigor, and innovation, with a steadfast focus on long-term commercial success. Each team member brings that mission and those values to life every single day. This recognition belongs to them."

About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard^® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck^® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.

About GenomeWeb
GenomeWeb is an independent online news organization based in New York. Since 1997, GenomeWeb has served the global community of scientists, technology professionals, and executives who use and develop advanced tools in molecular biology research and molecular diagnostics. GenomeWeb is a family brand of Crain Communications.

GenomeWeb's editorial mission is to cover the scientific and economic ecosystem enabled by high-throughput genome sequencing, delivering exclusive news and in-depth analysis of the rapidly evolving market. Its audience includes biopharmaceutical companies, research universities, biomedical institutes, clinical laboratories, and government organizations.

Forward-Looking Statements

This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid's clinical and preclinical studies; whether and when Lucid's products are cleared by regulatory authorities; market acceptance of Lucid's products once cleared and commercialized; Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, Lucid continues to monitor the COVID-19 pandemic and the pandemic's impact on Lucid's businesses. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid's future operations, see Part I, Item 1A, "Risk Factors," in Lucid's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-named-a-genomeweb-2025-best-places-to-work-top-ranking-honoree-302621712.html

SOURCE Lucid Diagnostics

FAQ

What award did Lucid Diagnostics (LUCD) win on November 20, 2025?

Lucid Diagnostics won its company size category in the GenomeWeb 2025 Best Places to Work program.

How does the GenomeWeb 2025 Best Places to Work honor affect Lucid Diagnostics (LUCD)?

The honor signals recognition for workplace culture, inclusivity, and professional development, as stated by the company.

Is Lucid Diagnostics (LUCD) part of a larger company or group?

Yes. Lucid Diagnostics is a commercial-stage diagnostics company and a subsidiary of PAVmed (Nasdaq: PAVM).

What qualities did GenomeWeb cite for Best Places to Work honorees?

GenomeWeb cited transparent communication, an inclusive work environment, professional development, and collaboration.

Who commented for Lucid Diagnostics (LUCD) about the GenomeWeb award?

Shaun O'Neil, President and COO of Lucid Diagnostics, commented that the recognition reflects the company's patient-focused culture and employee commitment.

When was Lucid Diagnostics announced as a GenomeWeb 2025 top-ranking honoree?

The company announced the recognition on November 20, 2025.